Literature DB >> 79026

Oral vancomycin for antibiotic-associated pseudomembranous colitis.

F Tedesco, R Markham, M Gurwith, D Christie, J G Bartlett.   

Abstract

Nine patients with antibiotic-associated pseudomembranous colitis were treated with oral vancomycin. All had severe diarrhoea, tissue-culture evidence of a clostridial toxin in stool, and typical lesions on sigmoidoscopic examination, despite discontinuation of all antimicrobials for periods of 10 days to 8 weeks. Oral vancomycin was given in doses of 2 g daily. All patients showed a good clinical response with gradual resolution of diarrhoea over 7 days and a rapid decrease in concentrations of the toxin in stools. Follow-up sigmoidoscopies in seven patients showed major improvement or complete clearing of lesions after 7-10 days of vancomycin treatment. The mean concentration of vancomycin in twenty-five stools obtained during treatment was 3100 microgram/g, levels in serum being very low. These results suggest a role for oral vancomycin treatment of antibiotic-associated pseudomembranous colitis which persists for extended periods despite discontinuation of the incriminated antimicrobial.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 79026     DOI: 10.1016/s0140-6736(78)91741-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  41 in total

Review 1.  Drug-induced Clostridium difficile-associated disease.

Authors:  M L Job; N F Jacobs
Journal:  Drug Saf       Date:  1997-07       Impact factor: 5.606

Review 2.  Treatment of refractory and recurrent Clostridium difficile infection.

Authors:  Christina M Surawicz; Jacob Alexander
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2011-04-19       Impact factor: 46.802

Review 3.  Clinical update for the diagnosis and treatment of Clostridium difficile infection.

Authors:  Edward C Oldfield; Edward C Oldfield; David A Johnson
Journal:  World J Gastrointest Pharmacol Ther       Date:  2014-02-06

4.  Bacitracin therapy in antibiotic-associated pseudomembranous colitis.

Authors:  F J Tedesco
Journal:  Dig Dis Sci       Date:  1980-10       Impact factor: 3.199

5.  Presence of Clostridium difficile toxin in guinea pigs with penicillin-associated colitis.

Authors:  S W Rothman
Journal:  Med Microbiol Immunol       Date:  1981       Impact factor: 3.402

Review 6.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

7.  Clostridium difficile colitis associated with the use of antineoplastic agents.

Authors:  S D Miller; H J Koornhof
Journal:  Eur J Clin Microbiol       Date:  1984-02       Impact factor: 3.267

8.  Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile.

Authors:  R P Bolton; M A Culshaw
Journal:  Gut       Date:  1986-10       Impact factor: 23.059

9.  Pseudomembranous colitis in a leukaemia unit: a report of five fatal cases.

Authors:  D W Milligan; J K Kelly
Journal:  J Clin Pathol       Date:  1979-12       Impact factor: 3.411

10.  Treatment of Clostridium difficile Infection.

Authors:  John R. Stroehlein
Journal:  Curr Treat Options Gastroenterol       Date:  2004-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.